Table 1. cALD patient and transplant... | American Society of Hematology

Table 1.

cALD patient and transplant characteristics (N = 66)

	Data
Age, y	8.3 (4.4-47.1)
Baseline Loes score	9 (1-19.5)
Baseline gadolinium intensity score	2 (1-3)
CSF total protein, mg/dL	37 (11-186)
Preparative regimen, n
Nonmyeloablative	14
Myeloablative	52
Stem cell source, n
Umbilical cord blood	34
Unrelated donor	11
Sibling marrow donor	19
Parent donor	2
Total nucleated cell dose, 10⁸ cells/kg	0.90 (0.24-8.25)
CD34 dose, 10⁶ cells/kg	1.43 (0.11-15.97)
ANC recovery, d	16 (9-45)
Platelet recovery, d	34 (13-244)
Day-60 CD15 chimerism, %	100 (14.1-100)
Day-60 CD3 chimerism, %	93.5 (0-100)

	Data
Age, y	8.3 (4.4-47.1)
Baseline Loes score	9 (1-19.5)
Baseline gadolinium intensity score	2 (1-3)
CSF total protein, mg/dL	37 (11-186)
Preparative regimen, n
Nonmyeloablative	14
Myeloablative	52
Stem cell source, n
Umbilical cord blood	34
Unrelated donor	11
Sibling marrow donor	19
Parent donor	2
Total nucleated cell dose, 10⁸ cells/kg	0.90 (0.24-8.25)
CD34 dose, 10⁶ cells/kg	1.43 (0.11-15.97)
ANC recovery, d	16 (9-45)
Platelet recovery, d	34 (13-244)
Day-60 CD15 chimerism, %	100 (14.1-100)
Day-60 CD3 chimerism, %	93.5 (0-100)

All data are median (range), unless noted otherwise.